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Abstract
Background: In type 2 diabetes mellitus both insulin resistance and hyperglycemia are considered responsible for
autonomic dysfunction. The relation between the autonomic activity, impaired fasting glycemia and impaired glucose
tolerance is, however, unclear. The purpose of this study was to evaluate and compare the circadian autonomic activity
expressed as heart rate variability (HRV) measured by 24-hours ECG recording in insulin resistant subjects (IR) with
characteristics as follow: IR subjects with normal oral glucose tolerance test results, IR subjects with impaired fasting
glucose, IR subjects with impaired glucose tolerance and subjects with type 2 diabetes mellitus.
Methods: Eighty Caucasian insulin resistant subjects (IR) and twenty five control subjects were recruited for the study.
IR subjects were divided into four groups according to the outcoming results of oral glucose tests (OGTTs): IR subjects
with normal glucose regulation (NGR), IR subjects with impaired fasting glycemia (IFG), IR subjects with impaired glucose
tolerance (IGT) and subjects with type 2 diabetes mellitus (DM). Autonomic nervous activity was studied by 24-hours
ECG recording. Heart rate variability analysis was performed in time and frequency domains: SDNN, RMS-SD, low
frequency (LF) and high frequency (HF) were calculated.
Results: The total SDNN showed statistically significant reduction in all four groups with insulin resistant subjects (IR)
when compared to the control group (p <0,001). During night LF normalized units (n.u.) were found to be higher in all
four groups including IR subjects than in the control group (all p < 0,001) and subjects with normal glucose regulation
(NGR), with impaired fasting glycemia (IFG) and with impaired glucose tolerance (IGT) were found to have higher LF n.u.
than those in the type 2 diabetes mellitus group. The linear regression model demonstrated direct association between
LF values and the homeostasis model assessment-index (HOMA-I), in the insulin resistant group (r = 0,715, p <0,0001).
Conclusion: The results of our study suggest that insulin resistance might cause global autonomic dysfunction which
increases along with worsening glucose metabolic impairment. The analysis of sympathetic and parasympathetic
components and the sympathovagal balance demonstrated an association between insulin resistance and sympathetic
over-activity, especially during night. The results indicated that the sympathetic over-activity is directly correlated to the
grade of insulin resistance calculated according to the HOMA-I. Since increased sympathetic activity is related to major
cardiovascular accidents, early diagnosis of all insulin resistant patients should be contemplated.
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Background
The sympathetic nervous system modulates both hepatic
glucose production and the glucose uptake in peripheral
tissues [1].
A relation between insulin resistance and cardiac auto-
nomic regulation has been identified: some studies dem-
onstrated that the increase of plasma insulin level was
related to increased urinary [2] and plasma norepine-
phrine. Other studies, performed by microneurography,
have shown that acute hyperinsulinemia increases sympa-
thetic activity in muscle nerves [3].
Although insulin resistance predisposes to cardiovascular
disease, its pathophysiology is poorly understood.
Analysis of heart rate variability (HRV), a non invasive
technique used to assess autonomic neural regulation, has
been successfully introduced to investigate the influence
of autonomic neuromodulation in several pathophysio-
logic conditions [4-8].
Several studies performed by spectral analysis of HRV
have shown sympathetic over-activity in insulin resistant
subjects with normoglycemia [9-11].
The relation between diabetes mellitus and impaired car-
diac autonomic activity has been identified: it is character-
ized by a reduced power in all spectral bands, impaired
sympathetic response, abnormal reduced total power with
unchanged low frequency/high frequency ratio (LF/HF
ratio) [12,13].
The relation between to autonomic activity, impaired fast-
ing glycemia and impaired glucose tolerance is, however,
unclear.
Sigh et al [14] observed that the HRV was inversely related
to plasma glucose levels: the total power reduction was
greater in diabetic patients than that in subjects with
impaired fasting glycemia. In Sigh's study the spectral
analysis of HRV was performed only in 24-hours of ECG
registration and the glucose metabolic impairment was
calculated on fasting plasma glucose levels without previ-
ous oral glucose tolerance tests (OGTTs). Doing so, it's
impossible to establish if some of these subjects with
impaired fasting glycemia could also be affected by diabe-
tes mellitus, identified by the criteria of The American
Diabetes Association (ADA).
We hypothesized that insulin resistance might be related
to sympathetic over-activity and that dysautonomia
increases if insulin resistance is associated with glucose
metabolic impairment.
To test this hypothesis we evaluated and compared the
variations of the circadian autonomic rhythm, measured
by means of heart rate variability (HRV) in insulin resist-
ant subjects (IR) divided in four groups: IR subjects with
normal glucose regulation (NGR), IR subjects with
impaired fasting glucose (IFG), IR subjects with impaired
glucose tolerance (IGT) and IR subjects with type 2 diabe-
tes mellitus (DM). The analysis of these groups allowed us
to demonstrate the dysfunction of autonomic system in
insulin resistant subjects and to estimate the specific role
of the progression of glucose metabolic impairment on
autonomic activity.
Methods
One hundred and fifty consecutive Caucasian subjects
were screened. Oral glucose tolerance tests (OGTTs) were
performed in all subjects after overnight fast. Blood sam-
ples for glucose and insulin tests were collected before and
2-hours after glucose load consisting in 75 g glucose anhy-
drate in 300 ml of water ingested over the course of 5 min-
utes. Moreover fasting plasma insulin levels were
measured to evaluate the insulin resistance according to
the homeostasis model assessment-index (HOMA-I).
Subjects with hypertension [15], obesity, dyslipidemia,
cardiac arrhythmias, microalbuminuria, other comorbid-
ity (such as renal failure, heart failure, liver diseases,
hypothyroidism and hyperthyroidism) and undergoing
drug treatment that could potentially disturb carbohy-
drate metabolism (glucocorticoids, furosemide, B-block-
ers, etc) and cardiac autonomic activity (B-blockers, anti-
arrhythmics, ACE-inhibitors) were excluded. Among
them one hundred subjects (age 51,44 +/- 0,67 years, 51
men and 29 women) were admitted in this study: twenty
subjects with normal OGTTs results and without IR (con-
trol group) and eighty with insulin resistance.
Height, weight and body circumferences were measured
in all subjects; body mass index (BMI, kg/m2) was calcu-
lated as weight divided by height squared; waist-to-hip
ratio (WHR) was defined as waist circumference divided
by hip circumference.
The eighty patients with insulin resistance were divided
into four groups following their OGTTs results as estab-
lished b the criteria of The American Diabetes Association
(ADA) [16]:
1) a group of subjects with normal glucose regulation
(NGR): fasting plasma glucose (FPG) < 5,6 mmol/L and 2-
hours plasma glucose (2-HPG) < 7,8 mmol/L.
2) a group of subjects with impaired fasting glycemia
(IFG): F.P.G. 5,6 – 6,9 mmol/L and H.P.G < 7,8 mmol/L.BMC Cardiovascular Disorders 2006, 6:19 http://www.biomedcentral.com/1471-2261/6/19
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3) a group of subjects with impaired glucose tolerance
(IGT): F.P.G < 7,0 mmol/L and 2-HPG 7,8–11.1 mmol/L.
4) a group of subjects with type 2 diabetes mellitus (DM):
F.P.G. ≥ 7,0 mmol/L or 2-H.P.G. 7,8 – 11.1 mmol/L.
The glucose levels were determined by the glucose oxida-
tive methods (Beckman Coulter, Inc., Fullerton, CA); the
coefficient of variation for this assay was less than 4%.
Insulin levels were measured in μU/ml by radioimmu-
noassay (Linco Research, Inc., St. Charles, MO). The lower
limit for detection of insulin was 3 μU/ml. The intra- and
extra-assay coefficients of variation were less than 4% and
10% respectively.
The control group consisted in sex and age matched
healthy and normoglycemic subjects without insulin
resistance.
Ethical approval was obtained from the Institutional Eth-
ics Committee of the Umberto I° Hospital. Written
informed consent was obtained from all participants; all
the investigations were performed in accordance with the
principles of the Declaration of Helsinki.
Insulin resistance
The insulin resistance was evaluated by the homeostasis
model assessment-index (HOMA-I) [17-19]. The HOMA-
I was calculated by the formula: fasting plasma glucose
(mmol/L) × fasting plasma insulin (μU/ml)/22,5 as
described by Matthews and coworkers [20]. Insulin resist-
ance was defined as the third and fourth quartiles of the
HOMA-I. The accuracy and the precision of the HOMA
methods have been compared to independent estimates
of insulin resistance [20].
HRV assessment
Autonomic nervous system function was evaluated by
heart rate variability (HRV) analysis during 24-hours ECG
recording. All Holter recording were performed using a
three-channel recorder. Cardiovascular variability was
analysed following the recommendations of the Task
Force of the European Society of Cardiology and the
North American Society of Pacing and Electrophysiology
[21].
Spectral estimates of R-R intervals were obtained from sta-
tionary regions free of ectopic beats and technical artifacts.
The standard deviation of normal-to-normal RR intervals
[SDNN (ms) correlated to total autonomic activity] and
the square root of the average of the sum of the squares of
the differences between adjacent NN intervals [RMS-SD
(ms) correlated to parasympathectic system] were calcu-
lated and were divided in two periods: night (0 a.m. – 6
a.m.) and day (7 a.m. – 9 p.m.). Fast Fourier Transform
was used to obtain power spectral estimates of HRV, total
power in the frequency range (0 – 0,40 Hz) was divided
into: very low frequency (VLF: < 0,40 Hz), low frequency
(LF: 0,04 – 0,15 Hz modulated by sympathetic system),
and high frequency (HF: 0,15 – 0,40 Hz mediated by par-
asympathetic system), the integrals underlying respective
power density function were measured and expressed in
absolute units (ms2/Hz). Each spectral component was
also presented in normalized units (n.u.) by dividing LF
or HF by total power minus the very low frequency (LF or
HF/total power – VLF). The LF/HF ratio, considered an
index of cardiac sympathetic/parasympathetic tone bal-
ance, was also calculated.
Patients were analysed for 24-hours at 10 minutes inter-
vals. Artificial data and arrhythmic events were excluded.
The 24-hour period was divided into four parts: night (0
a.m. – 6 a.m.), morning (7 a.m. – 12 a.m.), afternoon (1
p.m. – 6 p.m.) and evening (7 p.m. – 11 p.m.). Data anal-
yses were performed with Del Mar Avionics Accuplus 363,
Irvine California, USA. In ten healthy subjects reproduci-
bility was evaluated by means of the interclass correlation
coefficient (ICC) comparing baseline values with the
results obtained at the fourth week. ICC was > 0,7 for
HRV.
Statistical analysis
Statistical analysis was performed with SPSS 12,0 (SPSS
Inc., Chicago, IL, U.S.A.) for Windows XP. Normality tests
were performed on all data. Parametric data are expressed
as mean values +/- standard deviation (SD) or data with
multiple time points variables were analysed by the gen-
eral model ANOVA. Post hoc multiple comparisons were
performed using LSD test when ANOVA testing was signif-
icant (p < 0,05). Pearson correlation coefficients were
computes to qualify the relationship between the varia-
bles. Since the levels of the HOMA-I strictly depended on
fasting insulin and glucose concentration, we did not con-
sider these parameters in multiple regression analysis. P <
0,05 was considered statistically significant.
Results and discussion
Clinical characteristics
Clinical characteristics for each study-group are shown in
Table 1.
The groups were matched according to age, sex, anthropo-
metrical parameters (i.e. body mass index, waist and hip
circumferences, waist ratio) and smoking status.
Heart rate variability
Time domain
Table 2 shows the comparison of the autonomic measures
in time domain analysis of heart rate variability (HRV)
between the different groups. The total SDNN showed sta-BMC Cardiovascular Disorders 2006, 6:19 http://www.biomedcentral.com/1471-2261/6/19
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tistically significant reduction in the insulin resistant
groups when compared to the control group (p <0,001).
DM group had smaller SDNN than the NGR group and
the IFG group (p < 0,001, p:0,010, respectively). No sig-
nificant difference between the DM and the IGT groups
(p: 0,202) was identified. During night SDNN was signif-
icantly higher (all p < 0,001) in the NGR group and in the
control group than in the IFG, IGT and DM groups. In all
four groups with insulin resistant subjects, these results
showed a reduction of total autonomic activity.
There was no difference in RMS-SD in insulin resistant
subjects during night.
Frequency domain
The measures of total power in frequency domain analysis
of HRV are resumed in Table 3. The total power was statis-
tically reduced in the insulin resistant groups (p < 0.001).
No significant difference between the NGR. and the IFG
groups (p: 0.552) was identified. The IGT group showed
smaller total power than the IFG group (p: 0.002).
The normalized units (n.u.) are described in Table 4. The
total LF were higher (all p < 0.001) in the NGR, the IFG
and the IGT groups than in the DM and in the control
groups. LF were higher in the NGR group when compared
to the IFG group (p: 0.043) and there was no difference
between the DM group and the control group (p: 0.114),
between the IFG and the IGT groups (p: 0.077) and
between the NGR and the IGT groups (p: 0.828). HF were
lower in the NGR group (p < 0.001), in the IGT group (p
< 0,001) and in the DM group (p:0.02) than in the control
group. HF were lower in the NGR and in the IGT groups
than in the IFG group (p: 0.02, p: 0.04) and in the DM
group (p <0.001). There were no differences between the
NGR and the IGT groups and between the IFG and the DM
groups.
Table 2: Time domain measures for each insulin resistant group and control group.
NGR IFG IGT DM Controls P (ANOVA)
SDNN (ms) 130,9 ± 35,9* 117,9 ± 24,2* 103,1 ± 37,0*,** 89,6 ± 30,3*,** 176,6 ± 29,5 < 0,001
SDNN day (ms) 105,2 ± 28,3 109,4 ± 31,7 81,1 ± 18,6*,** 77,3 ± 23,5 *,** 120,2 ± 26,9 < 0,001
SDNN night 
(ms)
118,8 ± 46,1 71,9 ± 11,8*,** 77,2 ± 32,0*,** 69,0 ± 22,1*,** 119,5 ± 38,2 < 0,001
RMS-SD (msec) 43,15 ± 20,33 35,16 ± 10,06 27,19 ± 12,46** 32,78 ± 15,51** 36,75 ± 10,59 0,032
RMS-SD day 
(msec)
41,58 ± 18,14* 34,46 ± 10,47 23,93 ± 11,41** 32,34 ± 14,46** 31,37 ± 9,07 0,007
RMS-SD night 
(msec)
47,47 ± 29,26 36,78 ± 11,01* 30,76 ± 15,34*,** 32,43 ± 15,51*,** 47,47 ± 17,60 0,013
Results are expressed as mean ± SD for each group. P < .05 was chosen to be the threshold of statistical significance for ANOVA and LSD post hoc 
test. SDNN: standard deviation of all sinus rhythm RR intervals ms, RMS SD: the square root of the mean of the sum of the squares of differences 
between adjacent NN intervals, NGR: normal glucose regulation, IFG: impaired fasting glycemia, IGT: impaired glucose tolerance, DM: type 2 
diabetes.
* P < .01 for comparison with control group.
** P < .05 for comparison with NGR grou
Table 1: Clinical characteristics for each study-group of subjects with insulin resistance and control group.
NGT IFG IGT DM Controls p (ANOVA)
Sex (M/F) 12/8 14/6 12/8 13/7 15/5
Age (years) 49,1 ± 6,6 49,8 ± 6,5 53,6 ± 3,7 52,4 ± 4,7 53,0 ± 8,0 NS
BMI (kg/m2) 27,3 ± 4,9 28,1 ± 4,7 26,2 ± 3,01 27,3 ± 2,8 25,0 ± 5,1 NS
WHR 0,97 ± 0,07 0,96 ± 0,04 0,98 ± 0,06 0,97 ± 0,05 0,9 ± 0,06 NS
Fasting plasma 
insulin (uU/ml)
19,3 ± 4,3 10,9 ± 2,9 12.67 ± 2.14 10.2 ± 2.9 7,1 ± 0,2 <0.001
HOMA-I 4,4 ± 0,8 3,1 ± 0,8 3,1 ± 0,6 2,7 ± 0,4 1,4 ± 0,2
HR 74,7 ± 4,5 76,6 ± 10,6 76,7 ± 10,9 75,0 ± 12,7 70,2 ± 4,1 NS
SBP (mmHg) 123,2 ± 3,7 121,1 ± 5,3 117,3 ± 11,2 121,0 ± 6,3 120,2 ± 7,0 NS
DBP(mmHg) 80,0 ± 3,1 78,1 ± 4,0 77,1 ± 6,7 77,7 ± 3,8 78,8 ± 4,9 NS
Values are mean ± SD. P <0.05 was chosen to be the threshold of statistical significance for ANOVA. BMI: body mass index, HOMA-I: the 
homeostasis model assessment-index, WHR: waist to hip ratio, SBP: systolic blood pressure, DBP: diastolic blood pressure, HR: heart rate; NGR: 
normal glucose regulation, IFG: impaired fasting glycemia, IGT: impaired glucose tolerance, DM: type 2 diabetes.BMC Cardiovascular Disorders 2006, 6:19 http://www.biomedcentral.com/1471-2261/6/19
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Night (0 am – 6 am)
The insulin-resistant groups showed, in total power, sta-
tistically significant reduction when compared to the con-
trol group (all p < 0.001).
The total power showed statistically significant reduction
in IR groups significant reduction
LF were higher in the four groups with IR than in the con-
trol group (all p < 0.001) and in the NGR, IFG and IGT
groups when compared to the DM group [fig. 1]. HF were
lower in all insulin-resistant groups than in the control
group (all p < 0.001), and there were no differences
among the NGR, IFG and IGT groups.
In all insulin-resistant groups LF were higher than in the
control group (all p < 0.001), and in subjects with NGR,
IFG and IGT LF were increased than in the DM group [fig.
1]; HF were lower in all insulin-resistant groups than in
the control group (all p < 0.001), and among the NGR,
IFG and IGT groups the differences were not statistically
significant.
Morning (7 am – 12 am)
In total power during the morning significant differences
were no identified between the NGR group and the con-
trol group (p: 0.131). Normalized LF were not statistically
differet among in the NGR, the IGT and the control
groups and between the IFG and the DM groups (p:
0.140), but LF were higher in the NGR and the IGT groups
than in the IFG (p: 0.001, p: 0.046 respectively) and the
DM (all p < 0.001) groups. LF were lower in the IFG and
the DM groups than in the control group (p: 0.038, p <
0.001 respectively).
Table 3: Autonomic function measures expressed in absolute values for each insulin resistance group and control group
NGR IFG IGT DM Controls p (ANOVA)
Total power 
(msec2/Hz)
2263,9 ± 312,4* 2135,2 ± 422,5* 1432,3 ± 36,7* 317,3 ± 96,7* 3798,6 ± 758,6 < 0,001
LF (msec2/Hz) 332,1 ± 66,6* 258,3 ± 12,8* 236,11 ± 5,5* 18,6 ± 3,1* 692,8 ± 202,7 < 0,001
HF (msec2/Hz) 85,5 ± 36,1 134,4 ± 24,4 93,6 ± 1,2 17,9 ± 3,4 446,8 ± 102,4 < 0,001
R-R (ms) 936,1 ± 10,3 886,8 ± 36,5 888,2 ± 13,1 788,5 ± 100,4 983,2 ± 182,4 0,005
Night
Total power 
(msec2/Hz)
2705,7 ± 360,7* 1059,9 ± 85,2* 1187,8 ± 81,7* 338,6 ± 177,4* 4590,8 ± 332,6 < 0,001
LF (msec2/Hz) 992,2 ± 7,2 209,6 ± 19,3*,** 563,2 ± 12,1*,** 32,09 ± 0,8*,** 876,7 ± 343,1 < 0,001
HF (msec2/Hz) 320,4 ± 141,7 179,4 ± 106,1 145,2 ± 52,9 54,5 ± 22,6 1412,3 ± 731,6 < 0,001
R-R (ms) 1072,2 ± 36,0* 918,1 ± 127,2* 877,0 ± 125,4* 869,6 ± 73,5* 131,7 ± 148,1 < 0,001
Morning
Total power 
(msec2/Hz)
2068 ± 931,6 1944,8 ± 482,8* 1355,0 ± 824,8* 92,7 ± 11,9*** 3121,8 ± 683,0 < 0,001
LF (msec2/Hz) 701,7 ± 155,0 1210,2 ± 
556,9*,**
470,6 ± 181,5 40,0 ± 29,8* 1286,2 ± 420,7 < 0,001
HF (msec2/Hz) 245,8 ± 222,6 506,5 ± 66,0 236,4 ± 173,5 5,5 ± 0,2 605,3 ± 246,2 < 0,001
R-R (ms) 868,4 ± 106,5 932,8 ± 67,8 831,2 ± 92,3 753,1 ± 200,1 863,9 ± 216,0 NS
Afternoon
Total power 
(msec2/Hz)
2152,4 ± 500,1 1982,6 ± 1251,0 1446,9 ± 
90,2***
675,8 ± 
577,2*,**
2677,7 ± 1445,2 0,002
LF (msec2/Hz) 969,1 ± 658,4 640,7 ± 395,6 487,3 ± 76,5*** 69,3 ± 38,7* 898,6 ± 166,8 < 0,001
HF (msec2/Hz) 176,6 ± 84,7 231,0 ± 143,5 118,4 ± 13,6 58,9 ± 27,1 296,2 ± 90,8 <0,001
R-R (ms) 865,7 ± 50,0 849,0 ± 0,8 887,5 ± 131,2 793,8 ± 103,8 874,0 ± 185,7 NS
Evening
Total power 
(msec2/Hz)
1588,1 ± 756,9* 1452,2 ± 71,7* 1841,7 ± 
1024,3*
111,8 ± 7,8*,** 4032,3 ± 2296,4 < 0,001
LF (msec2/Hz) 728,4 ± 
403,7***
360,9 ± 54,6* 725,1 ± 
358,7***
41,6 ± 14,4* 1382,8 ± 1266,9 < 0,002
HF (msec2/Hz) 180, 2 ± 31,6 262,1 ± 171,0 394,7 ± 239,5 16,9 ± 7,4 775,9 ± 492,3 < 0,001
R-R (ms) 891,4 ± 29,1* 814,8 ± 85,1* 939,6 ± 36,0 743,7 ± 18,6* 1039,2 ± 215,0 < 0,001
Values are mean ± SD for each group, P <,05 was chosen to be the threshold of statistical significance for ANOVA and LSD post hoc test, NGR: 
normal glucose regulation, IFG: impaired fasting glycemia, IGT: impaired glucose tolerance, DM: type 2 diabetes, LF: low frequency, HF: high 
frequency, hours of Holter registration: night time = 0–6 am, morning = 7–12 am, afternoon = 1–6 pm, evening = 7–11 pm, LF/HF: low frequency/
high frequency.
* P <,01 for comparison with control group.
** P <,05 for comparison with NGR group.
*** p <,05 for comparison with controls.BMC Cardiovascular Disorders 2006, 6:19 http://www.biomedcentral.com/1471-2261/6/19
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Low frequency values during night in insulin resistant groups and controls Figure 1
Low frequency values during night in insulin resistant groups and controls. LF: low frequency, NGR: normal glucose 
tolerance, IFG: impaired fasting glycemia, IGT: impaired glucose tolerance, DM: type 2 diabetes.
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Table 4: Autonomic function measures, expressed in normalized units, for each insulin resistance group and controls.
NGR IFG IGT DM Controls P (ANOVA)
LF n.u. 70,1 ± 6,6* 65,7 ± 8,2*,** 70,3 ± 5,8* 59,0 ± 7,3 55,4 ± 7,5 0,000
HF n.u. 24,3 ± 6,5 28,5 ± 7,4 23,5 ± 6,5 32,6 ± 6,4 37,6 ± 7,5 0,000
LF/HF  3,1 ± 1,3 2,5 ± 0,8 3,3 ± 1,4 1,9 ± 0,5 1,4 ± 0,9 0,000
LF night n.u. 66,7 ± 9,8* 65,5 ± 8,4* 69,8 ± 5,3* 54,8 ± 11,9* 35,2 ± 5,9 0,000
HF night n.u. 26,7 ± 8,1 29,1 ± 6,5 24,9 ± 6,0 37,8 ± 10,9 58,6 ± 6,6 0,000
LF/HF night 2,9 ± 1,5 2,4 ± 0,9 3,0 ± 0,9 1,6 ± 0,7 0,7 ± 0,5 0,000
LF n.u. morning 72,4 ± 9,4 63,5 ± 9,2 69,5 ± 7,2 59,4 ± 6,6* 69,4 ± 8,4 0,000
HF n.u. morning 22,7 ± 7,1 28,6 ± 8,7 22,8 ± 7,9 34,1 ± 5,9 23,0 ± 7,1 0,000
LF/HF morning 3,9 ± 2,8 2,5 ± 1,4 3,6 ± 1,8 1,8 ± 0,5 3,6 ± 1,7 0,001
LF n.u. 
afternoon
69,2 ± 9,8 70,3 ± 12,1 72,1 ± 7,3 50,4 ± 7,2* 70,0 ± 6,6 0,000
HF n.u. 
afternoon
24,1 ± 9,8 27,3 ± 14,9 21,3 ± 8,0 34,6 ± 9,4 22,3 ± 5,1 0,002
LF/HF 
afternoon
4,0 ± 3,9 3,7 ± 2,6 4,1 ± 2,3 1,6 ± 0,7 3,6 ± 1,3 0,028
LF n.u. evening 72,1 ± 6,3* 64,9 ± 15,3*** 69,0 ± 7,9*** 59,6 ± 5,9 56,7 ± 7,7 0,000
HF n.u. evening 23,6 ± 6,1 27,6 ± 14,6 25,3 ± 6,7 33,2 ± 6,3 35,7 ± 9,1 0,001
LF/HF evening 3,2 ± 0,9 3,6 ± 3,2 3,0 ± 1,4 1,8 ± 0,5 2,0 ± 0,9 0,008
Values are mean ± SD for each group. P < .05 was chosen to be the threshold of statistical significance for ANOVA and LSD post hoc test. NGR: 
normal glucose regulation, IFG: impaired fasting glycemia, IGT: impaired glucose tolerance, DM: type 2 diabetes, LF: low frequency, HF: high 
frequency, hours of Holter registration: night time = 0–6 am, morning = 7–12 am, afternoon = 1–6 pm, evening = 7–11 pm, LF/HF: low frequency/
high frequency.
* P < .01 for comparison with control group.
** P < .05 for comparison with NGR group.
*** p < .05 for comparison with controls.BMC Cardiovascular Disorders 2006, 6:19 http://www.biomedcentral.com/1471-2261/6/19
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were reduced in the NGR and the IGT groups when com-
pared (with) to the IFG (p: 0.015, p: 0.031 respectively)
and to the DM groups (all p < 0.001) and in the IFG group
than in the DM group (p: 0.028). HF were higher in the
IFG and the DM groups than in the control group (p:
0.029, p < 0.001, respectively). The HF values were not
statistically different among the NGR, the IGT and the
control groups.
Afternoon (1 pm – 6 pm)
The total power in NGR and IFG was not statistically dif-
ferent versus control group (p: 0.258 and p: 1.37 respec-
tively). LF were lower in the DM group than in the other
groups (all p < 0.001) and HF were higher in the DM
group than in the NGR (p: 0.001), IGT (p < 0.001) and
control groups (p: 0.004). The LF and HF values were not
different among the NGR, IGT and control group.
Evening (7 p.m. – 11 p.m.)
The total power was statistically different in the NGR, the
IGF and the IGT groups when compared to that of the
control and the DM groups. LF were higher in the NGR
and in the IGT groups than in the DM group (all p <
0.001) and those in the control group (p < 0.001, p:0.002,
respectively), and LF values were higher in the IFG group
than in those in the control group (p:0.034), and there
was no significant difference between the NGR and the
IGT groups, between the IFG and the DM groups and
between the DM group and the control group.
The frequency domain analysis of HRV showed associa-
tion between insulin resistance and sympathetic over-
activity especially during night.
As demonstrated in figure 2 linear regression model
showed direct association between LF value and the
HOMA-I, in the insulin resistant group (r = 0,715, p <
0.0001).
A limit in this study is the use of the HOMA-index as a
conventional indicator of insulin resistance. The best
method for assessing insulin resistance is the glucose
clamp technique. However the HOMA model has proved
to be a robust clinical and epidemiological tool in descrip-
tion of the pathophysiology of diabetes and, as already
quoted in over 500 publications, it has become one of the
standard tools in the armamentarium of the clinical physi-
ologist [23].
Conclusion
Our study evaluates and compares the circadian auto-
nomic rhythm measured by heart rate variability (HRV),
obtained by 24-hours ECG Holter registration in insulin
resistant subjects with normal oral glucose tolerance test,
with impaired fasting glucose, with impaired glucose tol-
erance and with type 2 diabetes mellitus. The results of the
present study confirm that impaired autonomic activity
was present also in insulin resistant patients with normal
glucose metabolism and in those with impaired glucose
tolerance.
We demonstrated that the sympathovagal balance
(expressed by the LF/HF ratio) remains consistently
altered with a sympathetic over-activity during night in all
insulin resistant subjects. This altered balance is revealed
by the lack of increased parasympathetic component (HF
n.u.) and the lack of reduction in the sympathetic compo-
nent (LF n.u.).
The sympathetic over-activity is mainly shown in the non
diabetic insulin resistant groups rather than in the dia-
betic group: in fact in this group the circadian rhythm of
autonomic activity showed no changes as demonstrated
by the sympathovagal balance that remained stabile dur-
ing both night and day [fig. 3].
These observations showed that autonomic dysfunction is
present in all insulin resistant groups, but the subjects
with type 2 diabetes mellitus had greater autonomic dys-
function than the insulin resistant subjects in the NGR,
the IFG and the IGT groups had.
Moreover this study claims that the autonomic dysfunc-
tion (AND) is linearly related to insulin resistance. The
relationship between the sympathetic over-activity and
the increase of insulin resistance, calculated by HOMA-
Index, is showed in figure 2. Increase of HOMA-I value
was correlated to increase of the LF values (r = -0.718, p
<0.0001).
In the time domain analysis of HRV our study demon-
strated significant reduction of the total autonomic sys-
tem activity in all insulin resistant groups, expressed as
progressive decrease of the SDNN values from the NGR
the IFG, the IGT to the DM groups [fig. 4].
The data support the hypothesis that insulin resistance
might cause a global reduction of the autonomic nervous
system activity. Our study also demonstrated that the dys-
autonomia increases if insulin resistance is associated
with worsening glucose metabolic impairment. In the
NGR group the dysautonomia is due to the effect of hyper-
insulinemia, whereas in the IFG and in the IGT groups we
have found that the effects of moderate hyperinsulinemia
and of moderate hyperglycemia is directly implicated in
the dysautonomia.
Considering that sympathetic over-activity is related to
major cardiovascular accidents, early diagnosis and treat-
ment of all insulin resistant patients should be consid-BMC Cardiovascular Disorders 2006, 6:19 http://www.biomedcentral.com/1471-2261/6/19
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ered, especially in patients with sympathetic over-activity
and with I.F.G. and/or I.G.T nowadays called "pre-diabe-
tes".
We hypothesize that early treatment of insulin resistance
might determine reduction in dysautonomia and conse-
Circadian variation of LF/HF in insulin resistant subjects and in control group Figure 3
Circadian variation of LF/HF in insulin resistant subjects and in control group. White circles: groups with normal 
glucose tolerance; white triangles: groups with impaired glucose tolerance; black triangles: groups with impaired fasting glyc-
emia, black squares: groups with type 2 diabetes; white squares: controls, LF/HF: low frequency/high frequency.
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quently determine reduction of the risk of cardiovascular
mortality risk.
Other studies are necessary to determine the mechanism
whereby insulin resistance might be related to autonomic
dysfunction.
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